AirSculpt Technologies, Inc. (AIRS)

NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-10-23

$1.20-4.00%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge AirSculpt Technologies, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	34.38M
EPS	—	-0.025
FY 2026 · Annual
Revenue	$151M–$157M	151.06M
EPS	—	-0.08
FY 2027 · Annual
Revenue	—	155.11M
EPS	—	-0.045

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Stable leadership and execution	New management hires and stable guidance support a recovery.	Intact	Loss of key executives or leadership turmoil	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Move towards positive EPS	A primary condition in AirSculpt Technologies, Inc.'s published investment case. The stated target is EPS improves from -$0.03 in FY26 to closer to breakeven.	Improving	EPS remains below -$0.03 beyond FY27	Diluted EPS: $-0.02 per share FY2026-Q2; GAAP. Published target: EPS improves from -$0.03 in FY26 to closer to breakeven. Target period is not explicitly aligned with this observation. Source published Aug 10, 2026-0.02 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0c8676fe-67d8-4013-b9d8-09420f232977. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Full year 2026 revenue of $151M to $157M	The company affirms full year 2026 revenue guidance of $151M to $157M.	Intact	Annual revenue falls below $151 million in FY26	Revenue: $42.9M FY2026-Q2; GAAP. Published target: >= $151 million total revenue. Target period is not explicitly aligned with this observation. Source published Aug 10, 202642,900,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0c8676fe-67d8-4013-b9d8-09420f232977. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management reaffirmed full year 2026 revenue guidance at approximately $151 to $157 million. Revenue declined slightly from $44.0 million in 2025-Q2 to $42.9 million in 2026-Q2, reflecting a modest downward trend. The trajectory shows reaffirmation of guidance despite recent slight revenue declines, indicating management is maintaining its growth target. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 3
2026-07-25	Unavailable	Unavailable	1 / 3
2026-07-26	Unavailable	Unavailable	1 / 3
2026-07-27	Unavailable	Unavailable	1 / 3
2026-07-28	Unavailable	Unavailable	1 / 3
2026-07-29	Unavailable	Unavailable	1 / 3
2026-07-30	Unavailable	Unavailable	1 / 3
2026-07-31	Unavailable	Unavailable	1 / 3
2026-08-01	Unavailable	Unavailable	1 / 3
2026-08-02	Unavailable	Unavailable	1 / 3
2026-08-03	Unavailable	Unavailable	1 / 3
2026-08-04	Unavailable	Unavailable	1 / 3
2026-08-05	Unavailable	Unavailable	1 / 3
2026-08-06	Unavailable	Unavailable	1 / 3
2026-08-07	Unavailable	Unavailable	1 / 2
2026-08-08	Unavailable	Unavailable	1 / 3
2026-08-09	Unavailable	Unavailable	1 / 3
2026-08-10	Unavailable	Unavailable	1 / 3
2026-08-11	Unavailable	Unavailable	1 / 3
2026-08-12	Unavailable	Unavailable	1 / 3
2026-08-13	Unavailable	Unavailable	1 / 3
2026-08-14	Unavailable	Unavailable	1 / 2
2026-08-15	Unavailable	Unavailable	1 / 2
2026-08-16	Unavailable	Unavailable	1 / 2
2026-08-17	Unavailable	Unavailable	1 / 2
2026-08-18	Unavailable	Unavailable	1 / 2
2026-08-19	Unavailable	Unavailable	1 / 2
2026-08-20	Unavailable	Unavailable	1 / 2
2026-08-21	Unavailable	Unavailable	1 / 2
2026-08-22	Unavailable	Unavailable	1 / 2
2026-08-23	Unavailable	Unavailable	1 / 2
2026-08-24	Unavailable	Unavailable	1 / 2
2026-08-25	Unavailable	Unavailable	1 / 2
2026-08-26	Unavailable	Unavailable	1 / 2
2026-08-27	Unavailable	Unavailable	1 / 2
2026-08-28	Unavailable	Unavailable	1 / 2
2026-08-29	Unavailable	Unavailable	1 / 2
2026-08-30	Unavailable	Unavailable	1 / 2
2026-08-31	Unavailable	Unavailable	1 / 2
2026-09-01	Unavailable	Unavailable	1 / 2
2026-09-02	Unavailable	Unavailable	1 / 2
2026-09-03	Unavailable	Unavailable	1 / 2
2026-09-04	Unavailable	Unavailable	1 / 2
2026-09-05	Unavailable	Unavailable	1 / 2
2026-09-06	Unavailable	Unavailable	1 / 2
2026-09-07	Unavailable	Unavailable	1 / 2
2026-09-08	Unavailable	Unavailable	1 / 2
2026-09-09	Unavailable	Unavailable	1 / 2
2026-09-10	Unavailable	Unavailable	1 / 2
2026-09-11	Unavailable	Unavailable	1 / 2
2026-09-12	Unavailable	Unavailable	1 / 2
2026-09-13	Unavailable	Unavailable	1 / 2
2026-09-14	Unavailable	Unavailable	1 / 2
2026-09-15	Unavailable	Unavailable	1 / 2
2026-09-16	Unavailable	Unavailable	1 / 2
2026-09-17	Unavailable	Unavailable	1 / 2
2026-09-18	Unavailable	Unavailable	1 / 2
2026-09-19	Unavailable	Unavailable	1 / 2
2026-09-20	Unavailable	Unavailable	1 / 2
2026-09-21	Unavailable	Unavailable	1 / 2
2026-09-22	Unavailable	Unavailable	1 / 2
2026-09-23	Unavailable	Unavailable	1 / 2
2026-09-24	Unavailable	Unavailable	1 / 2
2026-09-25	Unavailable	Unavailable	1 / 2
2026-09-26	Unavailable	Unavailable	1 / 2
2026-09-27	Unavailable	Unavailable	1 / 2
2026-09-28	Unavailable	Unavailable	1 / 2
2026-09-29	Unavailable	Unavailable	1 / 2
2026-09-30	Unavailable	Unavailable	1 / 2
2026-10-01	Unavailable	Unavailable	1 / 2
2026-10-02	Unavailable	Unavailable	1 / 2
2026-10-03	Unavailable	Unavailable	1 / 2
2026-10-04	Unavailable	Unavailable	1 / 2
2026-10-05	Unavailable	Unavailable	1 / 2
2026-10-06	Unavailable	Unavailable	1 / 2
2026-10-07	Unavailable	Unavailable	1 / 2
2026-10-08	Unavailable	Unavailable	1 / 2
2026-10-09	Unavailable	Unavailable	1 / 2
2026-10-10	Unavailable	Unavailable	1 / 2
2026-10-11	Unavailable	Unavailable	1 / 2
2026-10-12	Unavailable	Unavailable	1 / 2
2026-10-13	Unavailable	Unavailable	1 / 2
2026-10-14	Unavailable	Unavailable	1 / 2
2026-10-15	Unavailable	Unavailable	1 / 2
2026-10-16	Unavailable	Unavailable	1 / 2
2026-10-17	Unavailable	Unavailable	1 / 2
2026-10-18	Unavailable	Unavailable	1 / 2
2026-10-19	Unavailable	Unavailable	1 / 2
2026-10-20	Unavailable	Unavailable	1 / 2
2026-10-21	Unavailable	Unavailable	1 / 2
2026-10-22	Unavailable	Unavailable	1 / 2
2026-10-23	Unavailable	Unavailable	1 / 2
2026-10-24	Unavailable	Unavailable	1 / 2

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	0	2
2026-06-01	0	2
2026-07-01	1	2
2026-08-01	1	2
2026-09-01	1	2
2026-10-01	1	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 1 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Stable leadership and executionQualitative condition
Move towards positive EPSDiluted EPS: $-0.02 per share
Full year 2026 revenue of $151M to $157MRevenue: $42.9M

Next proof point

Nov 6, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.0%Typical daily move · historical

Downside history

-89.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

AirSculpt Technologies, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

AIRS is a high-risk, loss-making healthcare business with recent financial performance described as strong relative to its industry. Its multi-year view is intact, but execution on profitability and new services remains uncertain.

What's priced into AirSculpt Technologies, Inc.

The valuation evidence points to AIRS being cheap versus peers, with expectations only slightly below the model’s view. Confidence in that comparison is low, and the evidence does not show a clear valuation cushion against operating setbacks.

What the fundamentals likely do

Near term, recent revenue has edged lower, adjusted EBITDA has declined, and management cut its 2026 adjusted EBITDA guidance. Consecutive earnings misses make the next quarter a key execution test, while management continues to affirm its revenue guidance and plans to expand services through a new partnership.

What AirSculpt Technologies, Inc. hinges on

The favorable case depends on AIRS reversing course and raising guidance next quarter, alongside continued strength from healthcare peers. The unfavorable case depends on further earnings weakness or a weakening jobs report deepening recession concerns for cyclical healthcare names.